Peter S. Kim

Peter S. Kim, listed as senior executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Merck & Co., Inc. and Entrada Therapeutics, Inc. In total, 44 filings cover trades dated from 15 January 2007 to 3 June 2024.

Both buying and selling appear: 13 purchases worth €1.3M, against 1 sale worth €14.9M. The net balance comes to €13.6M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 16 share grants and 10 option exercises. 2025 to date brings 2 purchases and no sales.

A typical purchase (the median) is worth €32k. Across 11 purchases, this insider has always bought alone, with no colleague buying within 30 days. Ninety days after publication, 11 purchases show a median change of +3.2%, with the price up in 82% of them. This is a record of the past, not a forecast.

On 18 June 2025 came the latest disclosure, an open-market purchase for €337k in Entrada Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.